img

Global Non-infectious Macular Edema Treatment Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-infectious Macular Edema Treatment Market Research Report 2024

Non-infectious Macular Edema Treatment refers to the treatment of Non-infectious Macular Edema by drugs or therapies such as anti-VEGF therapy, corticosteroids, immunosuppressive agents, and biological agents. The macula is a region of the center of the retina. Macular edema is the accumulation of fluid in the macula that causes the macula to swell and thicken, thereby distorting vision.
According to Mr Accuracy reports’s new survey, global Non-infectious Macular Edema Treatment market is projected to reach US$ 15240 million in 2034, increasing from US$ 10840 million in 2024, with the CAGR of 4.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-infectious Macular Edema Treatment market research.
Key companies engaged in the Non-infectious Macular Edema Treatment industry include Allergan, Amgen, Pfizer, Novartis AG, F. Hoffman-La Roche, AbbVie, Bayer AG, Valeant Pharmaceuticals and Alimera Sciences, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Non-infectious Macular Edema Treatment were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Non-infectious Macular Edema Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-infectious Macular Edema Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Allergan
Amgen
Pfizer
Novartis AG
F. Hoffman-La Roche
AbbVie
Bayer AG
Valeant Pharmaceuticals
Alimera Sciences
Clearside Biomedical
Segment by Type
Anti-VEGF Therapy
Corticosteroid
Immune Inhibitor
Biological Preparation
Other

Segment by Application


Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-infectious Macular Edema Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-infectious Macular Edema Treatment Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Anti-VEGF Therapy
1.2.3 Corticosteroid
1.2.4 Immune Inhibitor
1.2.5 Biological Preparation
1.2.6 Other
1.3 Market by Application
1.3.1 Global Non-infectious Macular Edema Treatment Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-infectious Macular Edema Treatment Market Perspective (2018-2034)
2.2 Non-infectious Macular Edema Treatment Growth Trends by Region
2.2.1 Global Non-infectious Macular Edema Treatment Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Non-infectious Macular Edema Treatment Historic Market Size by Region (2018-2023)
2.2.3 Non-infectious Macular Edema Treatment Forecasted Market Size by Region (2024-2034)
2.3 Non-infectious Macular Edema Treatment Market Dynamics
2.3.1 Non-infectious Macular Edema Treatment Industry Trends
2.3.2 Non-infectious Macular Edema Treatment Market Drivers
2.3.3 Non-infectious Macular Edema Treatment Market Challenges
2.3.4 Non-infectious Macular Edema Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-infectious Macular Edema Treatment Players by Revenue
3.1.1 Global Top Non-infectious Macular Edema Treatment Players by Revenue (2018-2023)
3.1.2 Global Non-infectious Macular Edema Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Non-infectious Macular Edema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-infectious Macular Edema Treatment Revenue
3.4 Global Non-infectious Macular Edema Treatment Market Concentration Ratio
3.4.1 Global Non-infectious Macular Edema Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-infectious Macular Edema Treatment Revenue in 2024
3.5 Non-infectious Macular Edema Treatment Key Players Head office and Area Served
3.6 Key Players Non-infectious Macular Edema Treatment Product Solution and Service
3.7 Date of Enter into Non-infectious Macular Edema Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-infectious Macular Edema Treatment Breakdown Data by Type
4.1 Global Non-infectious Macular Edema Treatment Historic Market Size by Type (2018-2023)
4.2 Global Non-infectious Macular Edema Treatment Forecasted Market Size by Type (2024-2034)
5 Non-infectious Macular Edema Treatment Breakdown Data by Application
5.1 Global Non-infectious Macular Edema Treatment Historic Market Size by Application (2018-2023)
5.2 Global Non-infectious Macular Edema Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Non-infectious Macular Edema Treatment Market Size (2018-2034)
6.2 North America Non-infectious Macular Edema Treatment Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Non-infectious Macular Edema Treatment Market Size by Country (2018-2023)
6.4 North America Non-infectious Macular Edema Treatment Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-infectious Macular Edema Treatment Market Size (2018-2034)
7.2 Europe Non-infectious Macular Edema Treatment Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Non-infectious Macular Edema Treatment Market Size by Country (2018-2023)
7.4 Europe Non-infectious Macular Edema Treatment Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-infectious Macular Edema Treatment Market Size (2018-2034)
8.2 Asia-Pacific Non-infectious Macular Edema Treatment Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Non-infectious Macular Edema Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-infectious Macular Edema Treatment Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-infectious Macular Edema Treatment Market Size (2018-2034)
9.2 Latin America Non-infectious Macular Edema Treatment Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Non-infectious Macular Edema Treatment Market Size by Country (2018-2023)
9.4 Latin America Non-infectious Macular Edema Treatment Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-infectious Macular Edema Treatment Market Size (2018-2034)
10.2 Middle East & Africa Non-infectious Macular Edema Treatment Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Non-infectious Macular Edema Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-infectious Macular Edema Treatment Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Non-infectious Macular Edema Treatment Introduction
11.1.4 Allergan Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.1.5 Allergan Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Non-infectious Macular Edema Treatment Introduction
11.2.4 Amgen Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Non-infectious Macular Edema Treatment Introduction
11.3.4 Pfizer Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-infectious Macular Edema Treatment Introduction
11.4.4 Novartis AG Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.4.5 Novartis AG Recent Development
11.5 F. Hoffman-La Roche
11.5.1 F. Hoffman-La Roche Company Detail
11.5.2 F. Hoffman-La Roche Business Overview
11.5.3 F. Hoffman-La Roche Non-infectious Macular Edema Treatment Introduction
11.5.4 F. Hoffman-La Roche Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.5.5 F. Hoffman-La Roche Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Non-infectious Macular Edema Treatment Introduction
11.6.4 AbbVie Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.6.5 AbbVie Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Non-infectious Macular Edema Treatment Introduction
11.7.4 Bayer AG Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 Valeant Pharmaceuticals
11.8.1 Valeant Pharmaceuticals Company Detail
11.8.2 Valeant Pharmaceuticals Business Overview
11.8.3 Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Introduction
11.8.4 Valeant Pharmaceuticals Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.8.5 Valeant Pharmaceuticals Recent Development
11.9 Alimera Sciences
11.9.1 Alimera Sciences Company Detail
11.9.2 Alimera Sciences Business Overview
11.9.3 Alimera Sciences Non-infectious Macular Edema Treatment Introduction
11.9.4 Alimera Sciences Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.9.5 Alimera Sciences Recent Development
11.10 Clearside Biomedical
11.10.1 Clearside Biomedical Company Detail
11.10.2 Clearside Biomedical Business Overview
11.10.3 Clearside Biomedical Non-infectious Macular Edema Treatment Introduction
11.10.4 Clearside Biomedical Revenue in Non-infectious Macular Edema Treatment Business (2018-2023)
11.10.5 Clearside Biomedical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-infectious Macular Edema Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Anti-VEGF Therapy
Table 3. Key Players of Corticosteroid
Table 4. Key Players of Immune Inhibitor
Table 5. Key Players of Biological Preparation
Table 6. Key Players of Other
Table 7. Global Non-infectious Macular Edema Treatment Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 8. Global Non-infectious Macular Edema Treatment Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 9. Global Non-infectious Macular Edema Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Non-infectious Macular Edema Treatment Market Share by Region (2018-2023)
Table 11. Global Non-infectious Macular Edema Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 12. Global Non-infectious Macular Edema Treatment Market Share by Region (2024-2034)
Table 13. Non-infectious Macular Edema Treatment Market Trends
Table 14. Non-infectious Macular Edema Treatment Market Drivers
Table 15. Non-infectious Macular Edema Treatment Market Challenges
Table 16. Non-infectious Macular Edema Treatment Market Restraints
Table 17. Global Non-infectious Macular Edema Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Non-infectious Macular Edema Treatment Market Share by Players (2018-2023)
Table 19. Global Top Non-infectious Macular Edema Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-infectious Macular Edema Treatment as of 2024)
Table 20. Ranking of Global Top Non-infectious Macular Edema Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Non-infectious Macular Edema Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Non-infectious Macular Edema Treatment Product Solution and Service
Table 24. Date of Enter into Non-infectious Macular Edema Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Non-infectious Macular Edema Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2023)
Table 28. Global Non-infectious Macular Edema Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 29. Global Non-infectious Macular Edema Treatment Revenue Market Share by Type (2024-2034)
Table 30. Global Non-infectious Macular Edema Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2023)
Table 32. Global Non-infectious Macular Edema Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 33. Global Non-infectious Macular Edema Treatment Revenue Market Share by Application (2024-2034)
Table 34. North America Non-infectious Macular Edema Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 35. North America Non-infectious Macular Edema Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Non-infectious Macular Edema Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 37. Europe Non-infectious Macular Edema Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. Europe Non-infectious Macular Edema Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Non-infectious Macular Edema Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 40. Asia-Pacific Non-infectious Macular Edema Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 41. Asia-Pacific Non-infectious Macular Edema Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Non-infectious Macular Edema Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 43. Latin America Non-infectious Macular Edema Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. Latin America Non-infectious Macular Edema Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Non-infectious Macular Edema Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 46. Middle East & Africa Non-infectious Macular Edema Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 47. Middle East & Africa Non-infectious Macular Edema Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Non-infectious Macular Edema Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 49. Allergan Company Detail
Table 50. Allergan Business Overview
Table 51. Allergan Non-infectious Macular Edema Treatment Product
Table 52. Allergan Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 53. Allergan Recent Development
Table 54. Amgen Company Detail
Table 55. Amgen Business Overview
Table 56. Amgen Non-infectious Macular Edema Treatment Product
Table 57. Amgen Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 58. Amgen Recent Development
Table 59. Pfizer Company Detail
Table 60. Pfizer Business Overview
Table 61. Pfizer Non-infectious Macular Edema Treatment Product
Table 62. Pfizer Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 63. Pfizer Recent Development
Table 64. Novartis AG Company Detail
Table 65. Novartis AG Business Overview
Table 66. Novartis AG Non-infectious Macular Edema Treatment Product
Table 67. Novartis AG Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 68. Novartis AG Recent Development
Table 69. F. Hoffman-La Roche Company Detail
Table 70. F. Hoffman-La Roche Business Overview
Table 71. F. Hoffman-La Roche Non-infectious Macular Edema Treatment Product
Table 72. F. Hoffman-La Roche Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 73. F. Hoffman-La Roche Recent Development
Table 74. AbbVie Company Detail
Table 75. AbbVie Business Overview
Table 76. AbbVie Non-infectious Macular Edema Treatment Product
Table 77. AbbVie Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 78. AbbVie Recent Development
Table 79. Bayer AG Company Detail
Table 80. Bayer AG Business Overview
Table 81. Bayer AG Non-infectious Macular Edema Treatment Product
Table 82. Bayer AG Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 83. Bayer AG Recent Development
Table 84. Valeant Pharmaceuticals Company Detail
Table 85. Valeant Pharmaceuticals Business Overview
Table 86. Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Product
Table 87. Valeant Pharmaceuticals Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 88. Valeant Pharmaceuticals Recent Development
Table 89. Alimera Sciences Company Detail
Table 90. Alimera Sciences Business Overview
Table 91. Alimera Sciences Non-infectious Macular Edema Treatment Product
Table 92. Alimera Sciences Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 93. Alimera Sciences Recent Development
Table 94. Clearside Biomedical Company Detail
Table 95. Clearside Biomedical Business Overview
Table 96. Clearside Biomedical Non-infectious Macular Edema Treatment Product
Table 97. Clearside Biomedical Revenue in Non-infectious Macular Edema Treatment Business (2018-2023) & (US$ Million)
Table 98. Clearside Biomedical Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-infectious Macular Edema Treatment Market Size Comparison by Type (2023-2034) & (US$ Million)
Figure 2. Global Non-infectious Macular Edema Treatment Market Share by Type: 2024 VS 2034
Figure 3. Anti-VEGF Therapy Features
Figure 4. Corticosteroid Features
Figure 5. Immune Inhibitor Features
Figure 6. Biological Preparation Features
Figure 7. Other Features
Figure 8. Global Non-infectious Macular Edema Treatment Market Size Comparison by Application (2023-2034) & (US$ Million)
Figure 9. Global Non-infectious Macular Edema Treatment Market Share by Application: 2024 VS 2034
Figure 10. Retail Pharmacy Case Studies
Figure 11. Hospital Pharmacy Case Studies
Figure 12. Other Case Studies
Figure 13. Non-infectious Macular Edema Treatment Report Years Considered
Figure 14. Global Non-infectious Macular Edema Treatment Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 15. Global Non-infectious Macular Edema Treatment Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Non-infectious Macular Edema Treatment Market Share by Region: 2024 VS 2034
Figure 17. Global Non-infectious Macular Edema Treatment Market Share by Players in 2024
Figure 18. Global Top Non-infectious Macular Edema Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-infectious Macular Edema Treatment as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Non-infectious Macular Edema Treatment Revenue in 2024
Figure 20. North America Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 21. North America Non-infectious Macular Edema Treatment Market Share by Country (2018-2034)
Figure 22. United States Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 23. Canada Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. Europe Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. Europe Non-infectious Macular Edema Treatment Market Share by Country (2018-2034)
Figure 26. Germany Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. France Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. U.K. Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Italy Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Russia Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. Nordic Countries Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Asia-Pacific Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. Asia-Pacific Non-infectious Macular Edema Treatment Market Share by Region (2018-2034)
Figure 34. China Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. Japan Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. South Korea Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. Southeast Asia Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. India Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. Australia Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Latin America Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. Latin America Non-infectious Macular Edema Treatment Market Share by Country (2018-2034)
Figure 42. Mexico Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Brazil Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Middle East & Africa Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Middle East & Africa Non-infectious Macular Edema Treatment Market Share by Country (2018-2034)
Figure 46. Turkey Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Saudi Arabia Non-infectious Macular Edema Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 48. Allergan Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 49. Amgen Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 50. Pfizer Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 52. F. Hoffman-La Roche Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 53. AbbVie Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 54. Bayer AG Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 55. Valeant Pharmaceuticals Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 56. Alimera Sciences Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 57. Clearside Biomedical Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed